Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.

HRS, serious complication of liver cirrhosis, and associated with high mortality without treatment, may benefit from terlipressin plus human albumin administration. In the absence of terlipressin, as in the USA, midodrine and octreotide plus human albumin are alternative treatments. In this trial, terlipressin plus human albumin resulted significantly more effective than midodrine and octreotide plus human albumin in improving renal function in patients with hepatorenal syndrome.